Patients receiving high-dose preparation for stem cell transplantation are at risk for organ dysfunction (OD). Signs of early OD include hypoxia, mental status changes, and liver dysfunction. These early signs have not been correlated with potential cytokine mediators. We compared plasma concentrations of IL-6, TNF-␣, and IL-10 in OD patients and controls. Cytokines were measured before preparation, 5 days before OD, day of OD, and 5 days after OD. TNF-␣ and IL-10 were not measurable prior to preparation. IL-10 was more likely to be measurable in OD patients than in controls 5 days prior to onset of OD (P = 0.039), on the day of OD (P = 0.023), and 5 days later (P Ͻ 0.0001). TNF-␣ was more likely to be measurable only on the day of OD (P = 0.0035). IL-6 was significantly elevated in OD patients at all time points. Patients who had measurable IL-6 on admission were 5.1 times more likely to develop OD (95% CI = 1.4-17.9; P = 0.011). Five days prior to OD for each 100 pg/ml increase in IL-6, patients were 2.75 times more likely to develop OD (95% CI = 1.3-5.8; P = 0.0087). The early elevation of IL-6 in patients who develop OD may help identify a high risk group where preventive therapies can be evaluated. Bone Marrow Transplantation (2001) 28, 889-893.
The etiology of organ dysfunction (OD) after hematopoietic stem cell transplant is complex and it is often difficult to identify causation. Its importance is related to the high mortality in patients who develop OD. 1 Because there is no single laboratory marker for OD, effort has concentrated on describing an objective set of clinical signs which can identify those patients with early OD. Our group has defined OD as the occurrence of any one of the following: subtle signs of mental status changes, hypoxia, weight gain and elevation in bilirubin. 1 Multiple organ dysfunction (MODS) would then be defined as developing two or more of these clinical signs or symptoms. Inflammation and thrombosis have been proposed as major clinical components of OD with the possible involvement of cytokine mediators of systemic inflammatory response syndrome such as tumor necrosis factor-alpha (TNF-␣) and interleukin-6 (IL-6).
2,3 IL-10 is an anti-inflammatory cytokine which has been correlated with improved outcomes in patients undergoing unrelated allogeneic transplantation. 4 Whether the etiology of OD is from high-dose preparation or from another insult, such as acute graft-versushost disease or infection, inflammatory cytokines have been suggested as important mediators. 5 The common pathway leading to organ damage from these inter-related but distinct insults may be the toxic effect of inflammatory cytokines on vascular endothelium leading to a proinflammatory and pro-coagulant state. For example, the observation that patients whose early OD progresses to MODS have high platelet transfusion requirements suggests there may be damaged endothelium leading to increased platelet binding. 6 Apoptosis can be induced in vascular endothelium by TNF-␣ and IL-6 and apoptotic endothelial cells have very potent procoagulant activity. 7 The preparative regimen is one potential etiology of OD. Methods to prevent regimen-related morbidity and mortality after stem cell transplantation have included modification of dose and schedule of chemoradiation, 8 use of cytoprotective drugs to reduce organ toxicity, 9 and pharmacokinetic monitoring of the drugs used in the preparative regimen. 10 Despite these interventions transplantrelated mortality in matched sibling transplant remains an important consideration occurring at a rate of about 10-20%. In matched unrelated transplantation and mismatched transplantation, early mortality can be more than double that of matched procedures. 11 These general methods of modifying toxicity have been variably successful.
The purpose of the following study was to identify potential mediators of OD which may be beneficial in developing more effective preventive therapies. With this in mind, we evaluated the plasma concentrations of three potential cytokine mediators of OD, IL-6, TNF-␣, and IL-10. A group of patients with early signs of OD were compared to control patients who went through their entire transplant course without signs of OD.
Materials and methods
The study was submitted to and approved by the University of Nebraska Medical Center Institutional Review Board. This study was designed to compare a case group of OD patients with a similar non-OD group. The study comprised 72 patients undergoing stem cell transplantation from 12 December 1994 to 9 November 1998. Of these patients, 56 were undergoing allogeneic transplantation for hematologic malignancy, while 16 were undergoing autologous stem cell transplant for various solid tumors. The allogeneic patients had their blood stored as part of an OD surveillance program while the autologous patients were a part of a study of antithrombin III where OD patients and controls were identified. 12 All patients were evaluated prospectively for early OD and morning blood samples were drawn starting the day of admission until the patient was discharged or on day 28 post transplant.
Assessment of organ function
Daily assessment of OD was performed. 1 Patients were considered to have OD if any one of the following clinical events occurred: pulmonary dysfunction indicated by an SAO 2 less than 70% on two separate occasions greater than 4 h apart, central nervous system dysfunction defined as a drop of greater than or equal to 4 points on a Folstein Mini Mental Status Exam and hepatic dysfunction defined by an elevation in bilirubin above 1.8 mg/dl, weight gain of 5% above admission weight, and abdominal pain. Patients who developed more than one of these clinical manifestations were considered to have MODS.
Allocation of patients into control and organ dysfunction groups
Both OD and control patients were identified based upon prospective evaluation of OD using the criteria described above. Control patients were those who did not develop signs or symptoms of organ dysfunction during their hospitalization. Control patients were selected to be similar to the OD group for age, gender, diagnosis, and type of transplant. A small number of OD patients (n = 5) did not have similar controls. For these patients, the closest match to transplant and preparative regimen was obtained.
Plasma collection and analysis of cytokine concentrations
Heparinized blood was collected daily for all patients. Blood was centrifuged and plasma collected and stored at −80°C for later analysis. IL-6, TNF-␣, and IL-10 concentrations were measured using a sandwich type ELISA (R& D Systems, Minneapolis, MN, USA). Cytokines were measured in 200 l of plasma and assays were performed in duplicate. For those concentrations that exceeded the upper limit of the standard curve 1:5 dilution was performed to maintain the concentration within the dynamic range of the assay. The lower limit of detection for IL-6, TNF-␣, and IL-10 was 0.7 pg/ml, 4.4 pg/ml, and 3.9 pg/ml, respectively. All ELISA assays had intra-assay and inter-assay precision of less than 5%.
Samples from the day prior to beginning preparation, 5 days before onset of OD, day of OD, and 5 days after the OD were thawed and analyzed for plasma cytokine concentrations in OD patients. Plasma from an identical day post transplant was analyzed in controls.
Statistical analysis
Cytokine concentrations in OD vs control patients were compared at each time point. Since there were many plasma samples with cytokine concentrations below the limit of detection of the assay for each of these samples, zero was assigned as the value. The number of samples with measurable cytokine concentrations were then compared between OD and controls. Comparisons of median IL-6 concentrations were performed using the Mann-Whitney U test, where there were sufficient numbers of measurable plasma concentrations. If there were insufficient numbers of measurable plasma concentrations, the values were dichotomized as detectable or undectectable and cases and controls were compared using the Fisher's exact test.
To assess the potential predictive value of the various cytokines for the development of OD, logistic regression was used. For those time points where there were many non-measurable cytokine concentrations the data were dichotomized as either detectable or undetectable. Where continuous data existed, they were analyzed as a continuous variable. The data were presented as odds ratios with 95% confidence intervals.
Results
Patient characteristics for the 36 patients undergoing stem transplantation who developed OD and the 36 control patients who did not develop OD are given in Table 1 . Groups were well matched for gender, age, type of transplant, diagnosis, serum creatinine, and bilirubin. Figure 1 gives a box plot for IL-6 concentrations at baseline, 5 days prior to OD, day of OD, and 5 days after OD. Comparison of medians was not meaningful for TNF-␣ and IL-10, given that many patients did not have measurable levels. Table 2 gives the percentage of samples with detectable TNF-␣ and IL-10 concentrations along with odds ratios and their 95% confidence intervals at each of the time points. It was rare to find measurable TNF-␣ or IL-10 concentrations in either group prior to preparation. TNF-␣ continued to be below the limit of detection 5 days before onset of OD, while IL-10 was significantly more likely to be measurable in the OD group leading to a 4.9 times greater risk of OD compared to patients with IL-10 concentrations below the limit of detection. The OD group had a significantly higher number of samples with measurable concentrations of both TNF-␣ and IL-10 at the time of OD and a similar difference existed 5 days after the onset of OD for IL-10. Table 3 compares IL-6 concentrations in OD and control groups and gives percentages detectable at baseline and medians at the other time points. Odds ratios and 95% confidence intervals are presented at all time points. Concentrations of IL-6 were significantly elevated in the organ dysfunction group at all time points. There was a significantly greater number of measurable IL-6 plasma concentrations in OD patients compared to controls at baseline prior to high-dose preparation. Patients with measurable ILBone Marrow Transplantation 6 concentrations at baseline were 5.1 times more likely to to develop OD. Analysis of IL-6 concentrations 5 days before OD showed that for each 100 pg/ml elevation in IL-6 concentrations there was a 2.75 times greater rate of OD.
Discussion
Organ dysfunction occurs frequently after stem cell transplantation. Patients developing OD may be identified by a decline in pulmonary, central nervous system, or hepatic function and often have corresponding laboratory abnormalities including a drop in antithrombin III and protein C concentrations and an increased platelet utilization. 6, 12 Regardless of which of these abnormalities is the first to be recognized, affected patients are at risk of progressing to MODS and death. 1, 13 The importance of developing these clinical abnormalities is difficult to overestimate, with one study reporting no mortality in patients without signs of early OD compared to 46% mortality in patients who showed signs of early OD. 12 Because each of the three single organ dysfunctions has similar laboratory correlates and clinical outcomes, some investigators feel they may be components of the larger syndrome called MODS.
Because OD associated with stem cell transplantation has many of the characteristics of a systemic inflammatory response syndrome such as sepsis, it may be that MODS after hematopoietic stem cell transplantation has a similar pathogenesis. TNF-␣ and IL-6 are pro-inflammatory cytokines which have been frequently evaluated in systemic inflammatory response syndrome. IL-6 and TNF-␣ have pro-inflammatory and pro-coagulation activity. Their effects are both direct by damaging vascular endothelium leading to reduced production of endogenous anti-coagulants such as ATIII and protein C, and indirect by stimulating the release of other destructive mediators. IL-6 and TNF-␣ are also auto-inducing, increasing the gene transcripts of themselves 14 with the net effect being an amplified inflammatory response which if unregulated can lead to a cytokine storm and organ damage.
In the following study, using subtle clinical signs and symptoms previously validated by our group, we identified patients at high risk for MODS. 6, 12, 13, 15 As previously stated, subtle changes in pulmonary, CNS, or liver function identifies a group of patients with high risk for death. Patients with pulmonary dysfunction or CNS changes had a 4.9-and 18-fold increased risk of dying after stem cell transplantation, respectively. 15 The lack of biochemical correlates has limited the generalizability of these criteria for early OD. The major goals of this study were to identify cytokine profiles that might help identify patients who will develop OD and to determine whether those cytokine profiles correlated with our early clinical criteria for OD.
There were significant elevations in IL-6, TNF-␣, and IL-10 in patients who developed OD. Therefore, patients with early signs of OD not only have a different prognosis, different concentrations of ATIII and protein C, and have different platelet requirements, this study shows that they also have different cytokine profiles.
A limitation of the current data is that IL-10 and TNF- ␣ were measurable in less than 50% of the OD patients. The ability to predict those patients at high risk for MODS will be limited if less than half of those with early OD have measurable systemic cytokine concentrations. The importance of systemic IL-6 exposure in the development of OD is well described in sepsis, where plasma concentrations have predicted for mortality. 16 In this study, IL-6 was measurable in about 50% of patients prior to preparation and was measurable in all patients including controls 5 days prior to OD. If patients had measurable levels at the time of admission they were five times more likely to develop OD. Five days prior to the onset of OD the absolute concentration of IL-6 was important. For each 100 pg/ml increase in IL-6 there was a nearly three-fold increase in OD risk. Since the median time to onset of OD was day 6 and all patients who were destined to develop OD did so by day 18, it may be possible to measure IL-6 on the day of admission, then once or twice per week during the first 2 weeks post transplant to identify patients who might benefit from pre-emptive therapy. Current limitations to this approach include the lack of a rapid assay for IL-6 and well established therapies to prevent OD.
In conclusion, we report that patients with early signs and symptoms of OD have elevated plasma cytokine concentrations compared to controls. IL-6 was consistently elevated 5 days prior to the clinical detection of OD and was often abnormal prior to beginning the preparative regimen. The early identification of patients developing OD may allow for targeted prevention or early treatment strategies including the administration of anti-coagulants, cytoprotective agents and anti-cytokine therapy in attempts to avoid potentially lethal MODS.
